SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?


To: Jeff Jordan who wrote (89397)3/21/2000 11:29:00 AM
From: Lane Hall-Witt  Respond to of 120523
 
ORTC PR -- 21 Mar 2000, 10:36 a.m. Eastern

CCS Shows Superiority Over Standard of Care in Interim Analysis of Ortec's Initial Venous Ulcer Trial

biz.yahoo.com

Note that the treatment of venous ulcers is a $1.345 billion per year; ORTC plans to apply to conduct pivotal trials for venous ulcers in the second quarter. ORTC hopes to go to market with CCS for venous ulcers in the first half of 2002.

Message 12947248